Virtually all solid tumors are dependent on a vascular network to provide them with the right amount of nutrients and oxygen. In that sense, low oxygen tension or hypoxia leads to an adaptive response that is transcriptionally regulated by the hypoxia-inducible factors (HIF), which are tightly controlled by the HIF prolyl hydroxylases (PHD). In this study, we show that inhibition of the oxygen sensor PHD2 in tumor cells stimulates vessel formation but paradoxically results in a profound reduction of tumor growth. This effect relies on the antiproliferative nature of the TGFb signaling pathway, in a largely HIF-independent manner. Moreover, our findings reveal that PHD2 has an essential function in controlling the dual nature of TGFb during tumorigenesis and may offer an alternative opportunity for anticancer therapy. Cancer Res; 71(9); 3306-16. Ó2011 AACR.
Introduction
Tumors can grow only when they have sufficient nutrients to sustain their metabolic needs for which they require a functional vascular system. This blood supply is the ratelimiting factor for tumor growth beyond a certain size. Moreover, many tumors proliferate so quickly that they exceed their own vascular supply, resulting in micro-environments characterized by low oxygen tension (hypoxia), a phenomenon that consequently leads to the expression of genes that promote survival of the cells, new vessel formation, and anaerobic metabolism (1) . This transcriptional response is, to a large extent, regulated by the hypoxia-inducible factor (HIF) family, which comprise complexes composed of a constitutive HIFb subunit and an oxygen-sensitive HIFa subunit that is degraded under normoxic conditions (2) . The overexpression of HIF has been detected in a wide variety of tumor types and directly correlates with tumor invasiveness and metastasis, as well as overall survival of patients (3) . In addition, HIF1a ablation in various tumor models often resulted in slower tumor growth accompanied by reduced vascular density (4, 5) . In this context, it is not surprising that this system is tightly regulated by a family of enzymes known as prolyl hydroxylase domain proteins (PHD; refs. [6] [7] [8] . Of the 3 major PHDs, PHD2 has been proposed to be the key oxygen sensor during normoxia and mild hypoxia (9) . The importance of this enzyme is underscored by the fact that inactivation of PHD2 severely deregulates normal embryonic development resulting in embryonic lethality by E14.5, whereas PHD1 À/À or PHD3 À/À mice develop normally (10) . Moreover, conditional somatic inactivation of PHD2 in mice causes an increase in erythropoietin production in the kidney, consequently leading to polycythemia, as has been observed in hypomorphic mutations in humans (10) (11) (12) (13) . Furthermore, heterozygous deficiency of PHD2 in mice has been shown to promote normalization of the endothelial lining and vessel maturation-a feature that redirected the specification of the endothelial tip cell to a more quiescent cell type during tumor development (14) . In addition to the role of PHD2 as an inhibitor of HIFa, it has been suggested that PHD2 can regulate the NFkB pathway via hydroxylation of the inhibitor of kB kinase (IKKb; ref. 15) . Overall, these data highlight the importance of PHD2 and its various functions. In the present study, we describe a number of mouse tumor cell lines that show a significant reduction in growth when PHD2 is silenced, regardless of the fact that the enzyme still plays a critical role in regulating angiogenesis. Not only do we provide evidence for a link between PHD2 and the TGFb signaling pathway but also our data suggest that changing PHD2 levels in tumor cells results in the transformation of TGFb from a tumor promoter to a tumor suppressor, also known as the "TGFb paradox" (16, 17) .
Materials and Methods

Cells
The murine osteosarcoma cell line LM8 (a gift from Dr. C. Beltinger, University Children's Hospital, Ulm, Germany; received in 2005) was grown in MEM-a medium. Lewis lung carcinoma (LLC) 3LL-D122 cells and a B16BL6 melanoma subline (a gift from Dr. C. Libert, DMBR-UGent, Belgium; received in 2005) were grown in Dulbecco's modified Eagle's medium (DMEM). After arrival, cells were cultivated and stored in numerous batches in liquid nitrogen. Stable cell lines (see further) were made from wild-type (WT) cells not passaged more than 5 times. After selection and cultivation, cells were stored in the same manner as WT cell lines. All cells were mycoplasma negative and tested with regard to morphology and growth rate in vitro and in vivo. No other authentication has been done. Cells were typically used before the fifth passage. All media were supplemented with 10% heatinactivated FBS, NEAA, and L-glutamine.
Mice and tumor models
Animal experiments were approved by the state of Saxony. All experiments were conducted with female C57BL/6 and C3H mice between 8 and 12 weeks of age (Taconic or the Dresden University of Technology). All mice received between 1 Â 10 6 (B16BL6) and 2 Â 10 6 (LLC and LM8) tumor cells injected into both flanks. All tumors were measured with calipers every 2 to 3 days, and the volume of each measurement was calculated as follows: (width 2 Â length)/2. Tumors were isolated unless explicitly mentioned otherwise (antiTGFb treatment) and processed immediately or stored at À80 C. Lung tissues for the detection of metastasis were prepared as formalin-fixed paraffin-embedded (FFPE) material. Circulating EGFP þ tumor cells were isolated at day 14 and counted from 1 mL of peripheral blood after the removal of red blood cells and adherence to a culture dish (ACK lysis; n ! 5). For the in vivo therapies, tumor cells were inoculated in mice and, when all tumors were palpable, either a neutralizing pan-TGFb antibody (2.5 mg per tumor per day) or an equal amount of immunoglobulin G (IgG) isotype control (R&D Systems) was injected adjacent to the tumor for 10 consecutive days ( Supplementary Fig. S5A ). Control animals received the diluent. Antibodies used included PHD2 (Novus Biologicals), HIF1a (Cayman chemical), b-actin (Sigma), cMyc (Santa Cruz), phosphorylated Smad2/3 [(pSmad2/3); Chemicon Int.], and IKKa and b (Cell Signaling). Specific bands on radiographic films were quantified using a BioRad densitometer and analyzed via the Quantity One analysis software.
In vitro doubling time Cells were plated in triplicate in 6-well dishes and, every 24 hours, were trypsinized and counted using a CASY cell counter. On the basis of the total cell numbers per time point, the doubling time for each cell line was calculated.
Immunohistochemistry and histology
To visualize the functional vasculature, mice were intravenously injected with Hoechst33342 prior to tumor isolation. Frozen sections measuring 8 mm were stained with platelet endothelial cell adhesion marker (PECAM/CD31) to visualize vessels. Nonfunctional vessels were identified on displaying PECAM Table S1 ).
Quantitative RT-PCR Total RNA was extracted from individual tumors using the RNeasy Mini Kit (Qiagen). cDNAs were synthesized using Superscript First-Strand synthesis (Invitrogen). Relative gene expression was determined using Maxima SYBR Green QPCR Master Mix (Fermentas) on an iCycler iQ (BIO-RAD). The DDCT method was used with normalization to both mTBR and EF2 as reference genes (see Supplementary  Table S2 ).
NFkB reporter assays
The NFkB Ready-To-Glow Luciferase Reporter Assay Kit (Clonetech) was used to monitor NFkB signal transduction. All LM8 cell lines were grown in culture medium and transfected with a pNFkB-MetLuc2-reporter vector. Metridia luciferase was measured 24 hours after transfection.
Statistics
Data and graphs represent mean AE SEM of representative experiments. Statistical significance was calculated by the Student's t test (Prism v4.02), with P < 0.05 considered statistically significant.
Results
PHD2 inhibition results in reduced tumor growth
The essential physiologic role of PHD2 in regulating HIF in vivo inspired us to examine its function in depth during tumor development. However, recent evidence showed that its tasks are not restricted to the inhibition of HIF alone (reviewed in ref. 18) . Furthermore, using a complete collection of human cancer microarray data (Oncomine Database), we found that significantly more tumor types (12.2%) overexpress PHD2 mRNA versus nontumoral tissue, than tumor types that underexpress the gene (2.2%; Supplementary Fig. S1A ; ref. 19) . Therefore, we conducted PHD2 knockdown studies using different mouse tumor cell lines in immunocompetent mice. Initially, we selected 2 independent shRNA sequences against PHD2. Both constructs stably overexpress shPHD2 (#1 or #2) and significantly knockdown PHD2 in a mouse osteosarcoma cell line (LM8). Of these, shPHD2#2 shows the most profound inhibition compared with shPHD2#1 ( Fig. 1A and Supplementary Fig. S1B ). In addition, stabilization of HIF1a in the PHD2 knockdown cells is already apparent under normoxic conditions and much more profound at 5% O 2 . On the other hand, sustained incubation at very low oxygen levels (1%) shows no significant difference in HIF1a levels compared with control LM8 cells, which confirms the limited activity of the PHD2 protein under permanent low O 2 conditions (ref. 9; Fig. 1A ). HIF2a could barely be detected under harsh conditions and was, therefore, not considered in the subsequent studies (data not shown).
To assess the development of these cells in vivo, we injected them in C3H mice and found that both independent shPHD2 clones grew significantly slower than the control cell lines [scramble (shScr) or nontransfected WT; Fig. 1B ]. In addition, at later stages, we detected a significant difference in growth pace between both shPHD2 clones that reflects their differential knockdown efficiency (Fig. 1C) . Moreover, virtually all shPHD2#2 LM8 tumors stopped growing and regressed over time. This resulted in complete loss of 75% of the tumors (9 of 12) and several tumor-free mice (4 of 6; animals were followed up until 3 months after the experiment). The differences observed in the mice, however, were not related to any fundamental defect of the cells themselves, because they all displayed similar growth rates in vitro ( Supplementary  Fig. S1C ). Western blot analysis of representative tumor sample lysates confirmed a clear reduction of PHD2 in LM8shPHD2 tumors 3 weeks after inoculation (Supplementary Fig. S1D ). Although our findings are in agreement with information obtained via the Oncomine Database, a recent publication showed inhibition of PHD2 in several human tumor cells resulting in massive induction of tumor growth (20) . We, therefore, silenced PHD2, using the most effective shRNA (shPHD2#2), in a mouse LLC and melanoma (B16BL6) cell line (Supplementary Fig. S1E and F) and inoculated these in C57BL/6 mice. Figure 1D and E shows that both PHD2-inhibited cell lines grow significantly slower than the corresponding controls. In addition, PHD2 inhibition was shown in representative lysates (Supplementary Fig. S1G and H). Thus, although there is evidence that inhibition of PHD2 is tumorigenic in immunocompromised mice, our data indicate the opposite effect in at least 3 different mouse tumor cell lines.
Tumor growth inhibition due to PHD2 modulation is mainly HIF independent PHD2 is considered the main HIF1a regulator in normoxia and mild hypoxia, although other interacting proteins have been described (9, 18) . Therefore, we targeted HIF1a in WT LM8 and shPHD2#2 cells (Supplementary Fig. S2A ). Interestingly, shHIF1a in LM8 cells resulted in a massive increase in tumor growth compared with shPHD2 and shScr tumors, indicating that HIF1a acts as a tumor suppressor. In addition, simultaneous knockdown of HIF1a and PHD2 drastically reduced tumor growth, again to a level not significantly different from shPHD2 tumors, showing that tumor growth retardation by silencing PHD2 is mainly HIF1a independent ( Fig. 2A and Supplementary Fig. S2B ). Consequently, we decided to investigate the role of PHD2 in the NFkB pathway. Not only does this transcription factor play a pivotal role in many different types of cancers (21) but also it was shown that PHD1 and PHD2 can hydroxylate/inactivate IKKb and, therefore, reduce NFkB activity (15) . However, using an in vitro reporter assay, we found that PHD2 silencing in LM8 cells significantly blocks the NFkB pathway (Fig. 2B ). This result is surprising but may be directly caused by reduced amounts of IKKa and IKKb proteins in the LM8shPHD2 cells, suggesting an alternative and probably indirect PHD2 regulation of these kinases (Fig. 2C) .
Inhibition of PHD2 induces vessel density
To investigate how the reduction of PHD2 in tumor cells blocks tumor growth, we defined the vessel density on tumor sections via immunohistochemistry. PECAM (CD31) staining revealed that LM8shPHD2 tumors display significantly higher vessel density (>35%) than scrambled tumors-a difference that we could also confirm in LLC tumors ( Fig. 3A and Supplementary Fig. S3A ). The finding that a reduction in tumor growth is related to an increase in blood vessels is contrary to the classical idea that angiogenesis promotes tumor growth. One plausible explanation is that the vessels in the shPHD2 tumors are not functional due to nonproductive angiogenesis, as described previously (22) . We, therefore, injected Hoechst33342 prior to isolation but found no difference in perfused (CD31
À ) vessels between shPHD2 and control tumors (Fig. 3B ). In addition, we checked for extravasation of tumor cells. Compared with controls, we found significantly less number of circulating EGFP þ tumor cells in the peripheral blood of shPHD2 tumor-bearing mice, and this is in agreement with the difference in volume of the primary tumors (Fig. 3C) . Moreover, metastatic nodules in the lungs of the latter mice were hardly detectable ( Supplementary Fig. S3B ). Furthermore, knockdown of PHD2 in tumor cells did not induce more programmed cell death in vivo (apoptosis), as shown by TUNEL staining, nor did it lead to more necrosis ( Fig. 3D and E) .
PHD2 silencing reduces cell proliferation in a TGFbdependent manner Because of the discrepancy between the elevated vessel density and the reduced growth of the tumor itself, we examined the proliferation rate of the tumor cells by means of Ki67 staining on tumor sections. These results clearly show that the proliferation rate of the tumor cells themselves, in both PHD2-inhibited tumor clones, is significantly reduced compared with control tumors (Fig. 4A) . In an attempt to identify regulators involved in this decreased proliferation, we examined the role of TGFb in our model. This family of cytokines exerts pro-as well as antiproliferative effects on different cell types and is an important regulator of the transcriptional repression of c-Myc through the canonical Smad-signaling pathway (23, 24) . Expression analysis of TGFb isoforms and their main receptors in LM8 tumor lysates revealed a significant induction for most of them in all shPHD2 tumors compared with controls ( Fig. 4B-F) . Furthermore, we were able to show induced activation of the TGFb pathway by means of pSmad2/3 (Fig. 4G ) as well as a significant repression of c-Myc in all LM8shPHD2 tumor lysates ( Fig. 4H and I ). Downstream, at the level of cell-cycle regulation, we found a clear up-regulation of cyclin-dependent kinase (CDK) inhibitors p15 LNK4B and p27 KIP1 (in particular, for shPHD2#2), but not p21
Cip1/WAF1 (Fig. 4J and L) . In LLC tumors, comparable differences were detected for c-Myc and the CDK inhibitors ( Supplementary Fig. S4A-C) but not for the members of the TGFb family or pSmad2/3 (data not shown).
Anti-TGFb treatment induces growth in PHD2-inhibited tumors
To determine the impact of TGFb on growth inhibition of these tumors, we developed an in vivo treatment method by which mice were injected daily (at different sites but near the tumor) with a pan-specific TGFb antibody that neutralizes all 3 TGFb isoforms ( Supplementary Fig. S5A ). In all mice containing one of the shPHD2 tumor cell lines, the antiTGFb treatment led to a significant induction of tumor growth compared with the isotype controls, showing the antiproliferative nature of TGFb in PHD2-silenced LM8 tumors ( Fig. 5A and B) . Congruent with these enlarged tumors, we observed a clear upregulation of proliferating tumor cells (Ki67 staining; Fig. 5C ). In addition, we evaluated the effect of the treatment on tumors of the best shRNA sequence (shPHD2#2) and found a significant drop of pSmad2 (no pSmad3 was detected on day 16; Fig. 5D ), upregulation of c-Myc (Fig. 5E) , and a partial reduction of p15 LNK1 (Fig. 5F ) but not of p27 KIP1 . Furthermore, inhibition of TGFb led to a moderate induction of vessel density, suggesting that the activity of the endogenous TGFb does not promote the induced angiogenesis seen in shPHD2 tumors ( Supplementary Fig. S5B ). On the other hand, an anti-TGFb treatment of shScr tumor-bearing mice resulted in a significant reduction of growth compared with the Figure 1 . PHD2 inhibition leads to stabilization of HIF1a and diminishes tumor growth. A, LM8 shRNA constructs (#1 or #2) were grown in 21% O 2 (¼ normoxia), 5% O 2 , or 1% O 2 for 24 hours and examined for PHD2, HIF1a, and b-actin via Western blot assay. B, shPHD2#1 and #2 or control LM8 (shScr or WT) were inoculated and measured every 2 to 3 days (n ¼ 12). *, P < 0.05; **, P < 0.01; and ***, P < 0.001 represent the difference for both shPHD2#1 and #2 versus shScr and WT samples. C, differential effect of both shPHD2 clones over a longer time period (n ¼ 12. **, P < 0.01; ***, P < 0.001 until day 21 represent the difference for both shPHD2#1 and #2 versus shScr and from day 26 on for shPHD2#2 versus shPHD2#1. shScr tumor-bearing mice were sacrificed at day 21 and shPHD2#1 at day 33. LLC (D) and B16BL6 (E) tumor cells knocked down for PHD2 (shPHD2#2) and control cells (shScr) were inoculated in immunocompetent C57BL/6 mice. Tumors were measured every 2 to 3 days (n ¼ 12). *, P < 0.05; **, P < 0.01. isotype controls, suggesting a pro-oncogenic effect of endogenous TGFb in control LM8 tumors (Fig. 5G) . Furthermore, we carried out the same treatment in C57BL/ 6 mice bearing different LLC tumors. Similarly, the 10-day treatment resulted in a significant induction of tumor growth in shPHD2#2 tumors as well as significant growth retardation in the control tumors ( Fig. 5H and I) . Moreover, if we combine the growth curves of LM8shPHD2#1, #2, and the LM8shScr tumors or those from LLCshPHD2#2 and LLCshScr, all treated with the TGFb antibody, it emerges that all the groups grow evenly fast and show no significant difference throughout the treatment (see Supplementary Fig. S5C and D) , suggesting that the TGFb pathway covers the entire growth difference induced by PHD2 silencing. In conclusion, these results not only show that the anti-TGFb treatment reaches exactly as far as the PHD2 silencing effect, in LM8 as well as in LLC, but also TGFb is an antiproliferative factor in tumors with reduced levels of PHD2 and is pro-oncogenic in the WT tumors.
Discussion
Recent evidence has shown that inhibition of PHD2 in human tumor cell lines leads to the induction of angiogenesis and thus enhanced blood supply and faster tumor growth (20) . In addition, in our study, using several mouse tumor cell lines, we found that the ablation of PHD2 resulted in an increase in vessel density, but that this was accompanied by an impressive decrease in tumor growth. Moreover, we found no evidence that this was due to nonproductive angiogenesis, as we have shown in the context of PHD4 overexpression (Klotzsche-von Ameln and colleagues, unpublished data) or in relation to the inhibition of delta-like ligand 4 (Dll4), as shown by others (22) . In contrast, the augmented vascularization was completely overruled by the antiproliferative effect of TGFb on the tumor cells themselves and not by the induction of apoptosis or necrosis, as has been shown for this growth factor in other settings (16, 25) . Moreover, this is the first time a direct relation between PHD2 silencing and regulation of the TGFb pathway has been shown in vivo. The impact of these findings was further supported by the repression of the proto-oncogene c-Myc in shPHD2 tumors. TGFb itself can only induce cell-cycle arrest at G 1 (26) by activating various antiproliferative responses, such as the transcriptional upregulation of CDK inhibitors, including p15 LNK4B , p21 Cip1/WAF1 , and p27 KIP1 , which specifically requires the downregulation of c-Myc (16, (27) (28) (29) . In addition, our results provide evidence that p15 Figure 4 . PHD2 silencing blocks tumor growth via the antiproliferative TGFb pathway. A, Ki67 staining on tumor sections expressing shPHD2 (#1 and #2) compared with control tumors (shScr) representing cell proliferation (n ! 6). Bars represent means AE SEM. **, P < 0.01. Scale bar represents 50 mm. B to F, shPHD2 (#1 and #2) and control tumors were isolated 21 days after inoculation and quantitative PCR (qPCR) was carried out (n ! 4). Average of all shScr samples is set as 1 AE SEM. *, P < 0.05; **, P < 0.01; and ***, P < 0.001. G, immunoblot on tumor lysates. All samples represent randomly chosen samples. Ratios are calculated as the band intensity of pSmad2/3 versus b-actin (n ¼ 4). *, P < 0.05; **, P < 0.01. Average of shPHD2 samples is set as 1 AE SEM. H, qPCR on shPHD2 and shScr samples (n ¼ 4). *, P < 0.05. I, a representative immunoblot on shPHD2#2 and control tumors for c-Myc and b-actin (n ¼ 4). Graph represents quantification of relative amount of c-Myc in the different groups. *, P < 0.05; **, P < 0.01; n ¼ 3, for shPHD2#1 and n ¼ 4 for others. Average of shPHD2 samples is set as 1 AE SEM. J to L, qPCR on shPHD2 and control tumors samples (n ! 4). Average of all shScr samples is set as 1 AE SEM. **, P < 0.01; N.S., not significant. This was accompanied by an upregulation of c-Myc and reduction of pSmad2 and p15 LNK4B . Conversely, the antibody treatment of control tumors resulted in significantly smaller tumors, suggesting that the knockdown of PHD2 switched the nature of TGFb from a pro-oncogenic to an antiproliferative factor. This dual role of TGFb has been the subject of several previous studies. Indeed, in normal cells and even during the early stages of tumor development, TGFb has been shown to act as a potent inhibitor of proliferation. However, during tumor progression, and for rather unclear reasons, TGFb can turn into an oncogenic factor, inducing cell proliferation and invasion (24, (30) (31) (32) . Nevertheless, our results imply that it is feasible to switch the nature of TGFb in aggressive and highly metastasizing cancer cells by knocking down the expression of PHD2, leading to slower growing as well as regressing tumors (Fig. 6) . The importance of this finding is underscored by the fact that the anti-TGFb treatment has a similar effect in the more aggressive LLC tumors. However, the LLCshPHD2 tumors do not express more TGFb ligands/receptors or pSmad2/3 than their controls, although they display TGFbrelated reduction of c-Myc and higher CDK inhibitor levels (p15 LNK4B and p27 KIP1 ). This implies that there are other cofactors, we have not revealed, that directly or indirectly regulate the antiproliferative TGFb pathway after inhibition of PHD2. Indeed, it is known that transcription factors E2F4/5 and DP1, together with corepressor p107, act as Smad2/3/4 cofactors, and thus link the TGFb pathway to c-Myc repression (33) . On the other hand, p15 repression can be directly regulated by c-Myc, similar to other factors such as Miz1 and KLF5. Induction of its expression can then, again, be supported by p300, acetylated KLF5, and FOX-O in combination with the R-Smads (34) . The difference between both cell lines might, therefore, lie in the expression or activity of one or more of these cofactors or in the difference in one of the TGFb members.
Moreover, our in vivo experiments suggest that the effect of inhibiting PHD2 in LM8 tumor cells is largely HIF-independent, an effect that has been previously described (20, 35) . For example, inhibition of PHD2 in human tumor cells was suggested to induce the NFkB pathway and lead to the overexpression of IL-8 (interleukin 8) and angiogenin, resulting in an enhanced influx of bone marrow-derived cells (BMDC) and angiogenesis (20) . We did not find any evidence of a differential influx of BMDCs in our tumors (S.M., B.W., unpublished results), nor did PHD2 silencing induce the NFkB pathway. On the contrary, we detected significantly less NFkB activity in LM8shPHD2 cells and reduced amounts of the NFkB activators, IKKa, and/or b (36), suggesting that, in our study, regulation of NFkB via PHD2 modulation does not occur through the classical pathway (15) . Whether these findings are directly associated to the PHD2-induced antiproliferative TGFb pathway still needs to be revealed.
Although it has been shown that TGFb can play a critical role in regulating both the activation and resolution phases of angiogenesis (37), we found that endothelial cell proliferation in shPHD2 tumors was still partially inhibited by TGFb. Indeed, anti-TGFb treatment in shPHD2 tumors resulted in a significant induction of Ki67 in tumor cells and an upregulation of vessel density. The factors responsible for the overall induced vascularization in our PHD2 knockdown tumors are unknown but not detrimental for the growth retardation in our study.
Silencing of PHD2 may induce tumor-suppressive effects as was implied by the analysis obtained via the Oncomine 
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Co-factors shPHD2 Figure 6 . PHD2 silencing blocks tumor growth via the antiproliferative nature of TGFb. In an aggressive and metastasizing osteosarcoma, the TGFb-Smad pathway is less active and leads to pro-oncogenic signaling. Silencing of PHD2 leads to the induction of TGFb members and a consequent switch to an antiproliferative system, which results in reduction of tumor growth and metastasis.
Database and our own tumor studies (20, 38, 39) . Indeed, although the discrepancy between our work and that of Chan and colleagues may be the difference in experimental setup (mouse tumor cell lines in immunocompetent mice vs. human xenografts in immunocompromised mice), it is more plausible to assume that the individuality of each tumor cell line accounts for the differences observed. Moreover, the role of PHD2 in supporting stromal cells must be considered, as it has been shown that PHD2 downregulation in endothelial cells normalizes the tumor vasculature, resulting in reduced malignancy and metastasis (14) .
Finally, our findings may have interesting medical implications because the TGFb pathway is currently being evaluated as a therapeutic target in an attempt to restore its normal function (40) (41) (42) . By using specific PHD2 inhibitors, certain tumors may transform to a less malignant and metastasizing phenotype by the re-induction of the antiproliferative TGFb pathway. However, more research is necessary in spontaneous developing tumors before any conclusions can be drawn regarding a useful therapy. At this stage, our results provide evidence for an HIF-independent role of PHD2 in the malignant transformation of TGFb, which will hopefully lead to a better understanding of the dual and complex role of this growth factor in oncogenesis.
